Phase 3 Study to Evaluate Ianalumab on Top of Standard-of-care Therapy in Patients With Systemic Lupus Erythematosus (SIRIUS-SLE 2)
Clinical trial NCT05624749 · ACTIVE_NOT_RECRUITING
Trial details
- NCT number
- NCT05624749
- Sponsor
- Novartis Pharmaceuticals
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2023-04-21
- Primary completion
- 2027-04-12
- Enrollment
- 288
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.